Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

This is a phase I/II, open-label, non-randomized, multicentre study to evaluate the clinical activity of vactosertib plus imatinib in desmoid tumor. Based on the background, TGF-β inhibition as

fibromatosis
imatinib
ejection fraction
vactosertib
measurable disease
  • 46 views
  • 02 Jul, 2022
  • 1 location
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin (IMPACT-TB)

The purpose of this study is to evaluate the safety, pharmacokinetics, and effects of imatinib on myelopoiesis in adults when given with and without isoniazid and rifabutin. The results of this

Accepts healthy volunteers
  • 0 views
  • 22 Mar, 2022
  • 1 location
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib, achievement of a

hydroxyurea
gleevec
philadelphia chromosome positive chronic myelogenous leukemia
basophils
leukemia
  • 10 views
  • 24 Mar, 2022
  • 1 location
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment

imatinib
kinase inhibitor
potassium
tyrosine
remission
  • 2 views
  • 14 Feb, 2022
  • 6 locations
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

must have previously attempted to discontinue imatinib. All patients must be restarted on imatinib at the time of relapse in order to be eligible for this trial.

  • 0 views
  • 14 May, 2022
  • 1 location
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in patients with the

  • 4 views
  • 30 Jun, 2022
  • 1 location
KISS Study: Kinase Inhibition With Sprycel Start up

controlled by the tyrosine kinase inhibitor (TKI) drug imatinib, which targets the consequences of the chromosomal abnormality, inducing a response and subsequent remission (as measured using molecular

hydroxyurea
kinase inhibitor
remission
basophils
leukemia
  • 653 views
  • 20 Mar, 2021
  • 9 locations
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells

  • 0 views
  • 27 Jun, 2022
  • 1 location
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

imatinib, more and more patients develop drug resistant to imatinib. In addition, the clinical data showed that the MRD negative rate in patients treated with imatinib combined with hyper CVAD was only 22

benzene ring
imatinib
tyrosine
prednisone
philadelphia chromosome
  • 0 views
  • 08 Apr, 2022
  • 1 location
A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as

  • 0 views
  • 26 Jan, 2021
  • 18 locations